DrugPatentWatch Database Preview
Details for Patent: 8,007,830
Which drugs does patent 8,007,830 protect, and when does it expire?
Patent 8,007,830 protects SINGULAIR and is included in one NDA.
This patent has twenty-eight patent family members in twenty-five countries.
Summary for Patent: 8,007,830
| Title: | Granule formation |
| Abstract: | The present invention relates to oral granules of montelukast sodium. |
| Inventor(s): | Down; Brian (Pierrefonds, CA) |
| Assignee: | Merck Frosst Canada & Co. (Quebec, CA) |
| Application Number: | 12/069,124 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,007,830 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; |
Drugs Protected by US Patent 8,007,830
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | SINGULAIR | montelukast sodium | GRANULE;ORAL | 021409-001 | Jul 26, 2002 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,007,830
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 385781 | Start Trial | |||
| Australia | 2002333134 | Start Trial | |||
| Brazil | 0213477 | Start Trial | |||
| Canada | 2463947 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
